What are the profit opportunities for the pharmaceutical industry in 2019?

[market analysis of chinapharma.com] New Year's weather, 2019 has set sail Now looking back at 2018, the keywords of "medical insurance cost control", "consistency evaluation" and "volume purchase" are striking The data shows that from January to may 2018, 442 national medical policies were issued, and in the second half of 2018, the medical policies of our country increased frequently, continuously affecting the new year Some pharmaceutical people believe that in 2019, the cold winter of the pharmaceutical industry has begun Does this mean that the days when pharmaceutical companies "lie down to make money" have passed, and there is no chance for the pharmaceutical industry to make money? The industry believes that even if the pharmaceutical industry really enters the cold winter, if enterprises want to survive, they will either innovate or transform, and will be eliminated if they wait and see, there is no other way to choose So, what are the profit opportunities for the pharmaceutical industry in 2019? The essence of pharmaceutical enterprise is innovation Pharmaceutical enterprise is not a simple processing and manufacturing, innovation is the essential requirement In 2019, with the policy support for innovative drugs and the promotion of the policy of "purchasing in quantity", innovative drugs will get more opportunities Therefore, the pharmaceutical enterprises with strength can continuously innovate products and enter the volume purchase with the help of R & D investment, so as to gain market share Some pharmaceutical enterprise personnel said that, especially the corporate culture, the way of thinking and the value orientation of the enterprise, will determine whether the enterprise can innovate "Because innovation doesn't mean that I affect income When you don't give 10% to innovate, if you don't innovate, you will gradually weaken If you innovate, no matter what kind of resources you use, one is that you have to innovate " The industry believes that the priority review system has accelerated the rate of drug market update, frequent national policies, encouraged more innovation in the field of drugs, and urged pharmaceutical enterprises to increase R & D investment In this context, it is expected that in 2019, some pharmaceutical enterprises will usher in the harvest period of new product listing, and the leading pharmaceutical enterprises with the ability of continuous innovation and commercial promotion will usher in development opportunities Enter the field of big health and give full play to the advantages of pharmaceutical enterprises According to the public data, in 2013, the scale of China's big health industry is close to 5 trillion yuan, accounting for 8% of the total GDP By 2020, the total scale of China's health industry will exceed 8 trillion yuan By 2023, the scale of large-scale health industry is expected to exceed 20 trillion yuan It can be seen that the prospect of big health industry in 2019 is considerable, which is suitable for pharmaceutical enterprises to set foot in Some pharmaceutical enterprise personnel said that with the increasingly fierce competition in the pharmaceutical industry, it is a feasible way for the long-term development of enterprises to expand to the large health field with broader development space In addition, pharmaceutical enterprises produce health products with the advantages of stronger professionalism and higher quality At present, many domestic pharmaceutical enterprises are marching into the field of big health For example, Yiling pharmaceutical industry is continuously increasing investment in health industry According to the disclosed announcement, Yiling pharmaceutical increased the capital of Yiling health city by 70 million yuan with its own funds After the capital increase, the registered capital of Yiling health city will be increased from 247 million yuan to 317 million yuan, and the proportion of the company's contribution to Yiling health city will be 97.79% In addition, in the field of children's health, in recent years, children's drugs and children's products have been highly valued Children's health industry is facing good development opportunities At present, a number of pharmaceutical companies are actively laying out children's health strategy and seizing market share
For example, dyne pharmaceutical has carried out the strategic layout of children's health in the early years, completed the transformation from a single children's pharmaceutical enterprise to a "children's health industry group", extended the production of children's nutrition supplements and treatment drugs to children's food, health food and other children's health fields; Kangzhi pharmaceutical acquired 51% equity of Jiuzhou hospital and 51% equity of Wanjia hospital, It formally entered the children's day safety and health industry with reproductive medicine technology as the core, and later planned to acquire 100% equity of Zhongshan cherish with 350 million yuan The author expects that with more and more pharmaceutical enterprises entering the big health industry, the development speed of the big health industry will continue to accelerate, and new competition will be launched among enterprises.